- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Trial completion date, Trial primary completion date, Metastases: A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) - May 18, 2022 P1, N=114, Recruiting, Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Jun 2023
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy, Metastases: A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (clinicaltrials.gov) - Apr 28, 2022 P2, N=402, Not yet recruiting,
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, Metastases: A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 4, 2021 P1/2, N=120, Recruiting, Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Jun 2023 Not yet recruiting --> Recruiting
|